Riskpilot← Back to searchSign inGet full accessPharmastrand AB
ABActiveOrg 5592253164Snapphanevägen 198Retail sale of pharmaceutical products · NACE 4773Est. 20191-4 employees
Revenue 2024
SEK 4,7M
+16% vs 2023
EBITDA margin
7.6%
-62% vs 2023
Equity ratio
43.5%
Financial strength
Net profit 2024
SEK 71K
-83% vs 2023
| Revenue | SEK 4,7M | +16% |
| EBITDA | SEK 352K | -62% |
| Net profit | SEK 71K | -83% |
| Total assets | SEK 1,5M | -32% |
| Equity | SEK 631K | -22% |
| Employees | — | — |
Legal name
Pharmastrand AB
Org number
5592253164
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
5 november 2019
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva apoteksverksamhet: Import, export samt handel med receptförskrivna läkemedel och egenvårdsprodukter (OTC-läkemedel) och därmed förenlig verksamhet. Bolaget ska även bedriva personaluthyrning
Address
Snapphanevägen 198
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 76 | 3 388 | 3 987 | 4 021 | 4 662 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −264 | 148 | 502 | 919 | 352 |
| Depreciation & amort. | −0 | −140 | −140 | −149 | −177 |
| EBIT | −264 | 8 | 362 | 770 | 175 |
| Net financials | — | −1 | −1 | −1 | −4 |
| Profit before tax | −264 | 7 | 361 | 559 | 111 |
| Tax | −0 | −0 | −22 | −132 | −40 |
| Net profit | −264 | 7 | 339 | 427 | 71 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 536 | 2 149 | 2 093 | 2 139 | 1 452 |
| Equity | 36 | 43 | 382 | 809 | 631 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 500 | 2 106 | 1 711 | 1 120 | 551 |
| Total debt | 1 500 | 2 106 | 1 711 | 1 120 | 551 |
EBITDA margin
7.6%
This company
15.8%
Market median
-52% vs market
20202024
Equity ratio
43.5%
This company
38.2%
Market median
+14% vs market
20202024
Return on equity
11.3%
This company
18.4%
Market median
+39% vs market
20202024
Net profit margin
1.5%
This company
8.1%
Market median
-81% vs market
20202024
Asset turnover
3.21×
This company
1.12×
Market median
+187% vs market
20202024
Debt / equity
1.30×
This company
0.62×
Market median
-110% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-11-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
LA Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (2) | ||
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmastrand AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leith Abdul Wahid Yassir | Chief Executive Officer | 0 companies |
| Mejs Abdulwahid Yassir | Board of Directors | 0 companies |
| Lilas Yassir | Board of Directors | 0 companies |
| Shaymaa Talat Saleh Abualreesh | Board of Directors | 0 companies |
| Mohammed Talat Saleh Abualreesh | Deputy Board Member | 0 companies |